The device was never the problem.
A Korean manufacturer we spoke with had done everything right. Their ultrasound system was selling across Asia and Europe. MFDS approval at home. CE marking in the EU. A clean ISO 13485 certificate. Clinical data that had satisfied three regulators.
They appointed an Indian distributor who offered to "handle the registration," shipped over the same technical file that had cleared Europe, and told their board India would be revenue-generating within two quarters.
Fourteen months later they had no licence, a deficiency letter they didn't fully understand, a distributor relationship they wanted out of but couldn't leave, and a competitor — with a demonstrably inferior device — already installed in the hospitals they had been targeting.
Nothing about that story is unusual. India is one of the fastest-growing medical device markets in the world, and a large share of what it consumes is imported. It is also a market where excellent products routinely stall at the paperwork, not the product. Here are the five traps that do the damage — and what an entry designed properly looks like instead.
Global approvals are evidence for an Indian application. They are not a shortcut through it, and they do not decide your Indian risk class. India runs its own classification logic under the Medical Device Rules, 2017 — and everything downstream hangs off it.
Trap 1: Filing in the wrong risk class
India sorts every device and IVD into four risk classes — A (low), B (low–moderate), C (moderate–high) and D (high). The class decides which authority reviews you, how much clinical evidence you must produce, what you pay, and how long you wait.
Here is what catches exporters: classification follows intended use and risk under Indian rules, not the class your device carries at home. A product that is comfortably mid-tier in Korea or the EU can land a rung higher in India. And the difference between classes is not cosmetic — a Class C or D file goes through Subject Expert Committee evaluation and demands clinical investigation data or genuinely robust published evidence, a risk management file, sterilisation validation and biocompatibility data. A Class A or B file does not.
File in the wrong class and you don't get a polite correction. You get months of review, a deficiency letter, and a restart — with your competitors moving the whole time. CDSCO has been tightening precisely here: dedicated risk-classification application routes now exist for medical devices and for IVDs, and licences are not issued against devices whose class has not been settled.
Settle classification in writing, with reasoning, before anyone starts assembling a dossier. It is the single highest-leverage decision in an India entry, and it costs a fraction of what re-filing costs.
Trap 2: The Device Master File with a new cover page
The second trap is the most tempting, because it looks like efficiency. You already have a technical file that satisfied a demanding regulator. Why rebuild it?
Because Indian reviewers are not reading your file the way the notified body did. They read the whole submission as one story — classification, intended use, device description, model numbers, manufacturer address, labelling, Instructions for Use, validation data, post-market evidence — and they check whether it is internally consistent. A Device Master File lifted straight from a CE or FDA submission is the single most reliable predictor of a long review cycle.
What actually triggers queries is rarely dramatic. It is a model number that appears one way on the label and another in the technical file. An intended-use statement that is broader in the brochure than in the dossier. A manufacturer address that differs by a line between the Free Sale Certificate and the application. Each of these is individually trivial. Each one costs a query cycle, and query cycles are measured in weeks.
Your pack needs a Device Master File and Plant Master File built for CDSCO, a Free Sale Certificate from your home authority, your ISO 13485 and existing approvals presented the way Indian reviewers expect to see them — and, above all, no contradictions between any two documents in the bundle.
Trap 3: Letting your distributor own your licence
This one is structural, and it is the trap that hurts longest.
Under MDR 2017, a foreign manufacturer cannot hold an Indian import licence directly. You must appoint an Authorised Indian Agent — an Indian entity holding a valid wholesale licence, empowered by Power of Attorney. That agent files the application in Form MD-14, holds the resulting Form MD-15 import licence, answers CDSCO's queries, and carries post-market and adverse-event responsibilities.
So far, so procedural. The commercial consequence is where brands get hurt: whoever holds the licence effectively holds your market access.
When the agent and the distributor are the same company — which is exactly what the convenient offer to "handle registration for you" produces — your regulatory approval is welded to a commercial relationship. If that distributor underperforms, or the terms sour, or you simply want to go multi-channel, you are not having a normal commercial negotiation. You are negotiating with the party that controls your right to sell. Changing distributor can mean re-doing your licence and losing the calendar all over again.
An agent arrangement built for compliance rather than for distribution keeps your licence portable — so you can change your route to market without restarting your regulatory clock. Decide this at the start; it is very hard to unwind later.
Trap 4: Treating labelling as a printing problem
A device can be fully approved and still sit in a customs shed, or get rejected by a hospital's procurement team, because of what is printed on the box.
India layers two regimes on top of each other. MDR 2017 labelling governs the device-specific content. Then, because your product is also a packaged commodity being sold commercially, Legal Metrology declarations apply — importer name and address, country of origin, and the other mandatory particulars. Miss either layer and the goods stop moving.
This is entirely avoidable, and it is the cheapest problem on this list to prevent — provided somebody is looking at both regimes at once, before the artwork goes to print rather than after the container lands.
Trap 5: The clock nobody diarised
Approval is a milestone, not a finish line — and Indian medtech compliance has a quiet trap built into it.
Your MD-15 import licence is valid in perpetuity, which sounds like the end of the story. It isn't. That perpetual validity is conditional on paying a licence retention fee before the completion of each five-year period from the date of issue. Miss it and CDSCO can suspend, and ultimately cancel, the licence.
Think about how that failure actually happens. The regulatory consultant who ran your original filing was engaged for a project that ended years ago. The distributor who holds the agent role has staff turnover. Nobody at your head office in Seoul or Stuttgart has "India retention fee" in a calendar five years out. And then a shipment stops at the border for a reason nobody can immediately explain.
The same applies to the rest of the post-market obligations: surveillance, adverse-event reporting under India's materiovigilance framework, recalls, and licence variations every time you change a model, a manufacturing site or an intended use. These are ongoing duties, not one-off tasks.
What a properly designed India entry looks like
Run in the right order, this is a manageable programme rather than a fourteen-month improvisation:
| Stage | What has to be true before you move on |
|---|---|
| 1. Classify | Risk class and licensing route settled in writing, with the reasoning — before any dossier spend. |
| 2. Structure the agent | An Authorised Indian Agent with real regulatory capability, and a structure that does not hand a distributor control of your licence. |
| 3. Build the dossier | Device and Plant Master Files built for CDSCO, existing approvals mapped in, and every model number, address and intended-use statement reconciled across the pack. |
| 4. File and defend | MD-14 submitted on the CDSCO portal, with queries and deficiency letters answered fast and consistently — this is where months are won or lost. |
| 5. Land the goods | MDR and Legal Metrology labelling correct, HS classification and landed cost modelled, customs cleared against the licence. |
| 6. Stay licensed | Post-market surveillance, adverse-event reporting, variations — and the retention fee tracked so the licence never lapses. |
One detail worth stealing regardless of who you work with: while your main licence is under review, a test licence lets you import limited quantities for demonstration, evaluation or clinical investigation. Brands that use that window to build clinician familiarity and tender references arrive at approval with demand already waiting. Brands that treat approval as the starting gun arrive and then start selling from zero.
We classify first and put it in writing. We structure the Authorised Indian Agent relationship so your licence stays portable. We build the Device and Plant Master Files for CDSCO rather than recycling your CE pack, file MD-14 and defend every query. Then we keep you compliant — labelling with Product Label Guru, landed cost and HS classification with TariffProof, and post-market surveillance, variations and retention-fee tracking so nothing quietly lapses. One partner, from classification to the shelf. See our Medical Devices & CDSCO services →
The bottom line
India rewards the brands that treat regulatory work as market strategy rather than paperwork to delegate. The devices that win here are rarely the ones with the best specification sheet — they are the ones whose makers got the risk class right, kept control of their own licence, filed a dossier that told one consistent story, and were still compliant five years later.
Your device is already good enough for India. The question is whether your entry plan is.
Planning an India launch, or stuck mid-application? Talk to Launch Rocket for a device classification review — we'll confirm your Indian risk class, map the licensing route with realistic timelines and costs, and tell you honestly what your current dossier is missing. Or explore our full Medical Devices & CDSCO services.
This article is general information for medical device manufacturers, importers and procurement teams, not legal or regulatory advice. It reflects the framework of the Medical Device Rules, 2017 and CDSCO practice as at August 2026. Classification outcomes, evidence requirements, fees and timelines are product-specific and are revised by the authorities from time to time — confirm the position for your device before acting. Opening illustration is a composite of common entry scenarios, not a specific client.